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Background
Failure to efficiently degrade the DNA of apoptotic cells
activates innate immunity causing chronic arthritis. If
deficient, Dnase I could lead to accumulation of undi-
gested DNA which induce activation of phagocytes and
production of proinflammatory cytokines, notably TNF.
Methods
The study was performed in 25 JIA patients who donated
paired serum samples prior and one year after continous
etanercept therapy. Basic clinical data (six core set varia-
bles defined in ACR PEDI outcome score) were recorded
along with alkalyne DnaseI serum levels using the method
where acid soluble nucleotides are determined spectro-
photometrically at 260 nm. Treatment schedule of etaner-
cept was 0, 4 mg/kg body weight subcutaneously twice
weekly.
Results
JIA patients mean age was 14,7 +/- 4,22 and disease dura-
tion is 6,59 +/- 2,76. Disease type distribution was 8% sys-
temic, 28% polyarticular RF-, 25% polyarticular RF+, 17%
ERA and 21% extended oligoarticular JIA. Summary of
data results prior and after anti TNFα therapy: ESR 26,88
vs. 15,52 (p < 0,01); patientVAS 40,24 vs. 24,40 (p <
0,05); physicianVAS 38,08 vs. 10,32 (p < 0,01); CHAQ
0,674 vs.0,375 (p < 0,01); LOM 15,52 vs. 11,68 (NS); AA
9,24 vs.2,64 (p < 0,01). DNaseI levels were significantly
lower prior (2.934 U/l) compared to values after one year
therapy (4,184 U/l; p < 0,01). We have found correlation
between DNaseI levels and AA (r = -0,993 p < 0,5) and
other clinical outcome variables prior and after therapy.
Conclusion
JIA patients with active disease have decreased DNase I
levels. Our results indicate significant increase of DNaseI
in the sera of JIA patients after one year of anti TNFα ther-
apy which was associated to the disease clinical improve-
ment.
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